TENAX THERAPEUTICS INC (TENX)
US88032L6056 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to...
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ:TENX) just reported results for the fourth quarter o...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with...
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company...
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment...
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...
ACB Stock Alert: The $50 Million Reason Aurora Cannabis Is Up Today
Aurora Cannabis stock is rising higher on Thursday as ACB investors react to the company acquiring MedReleaf Australia for $50 million.
Why Is Disney (DIS) Stock Up 9% Today?
Disney stock is gaining on Thursday as investors in DIS shares celebrate the company's strong earnings report for the first quarter of 2024.
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
Tenax Therapeutics stock is falling on Thursday after the company announced the pricing of a public offering for TENX shares.
Tenax Therapeutics stock sinks after it prices its public offering (NASDAQ:TENX)
Tenax Therapeutics prices public offering at $5.65 per share, raising $9.04M. Shares plummet 64.24% in pre-market trade.
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting Thursday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will...
Tenax stock surges after patent win (NASDAQ:TENX)
Tenax Therapeutics (TENX) stock saw a 52% surge after US regulators endorsed its patent application for heart failure therapy, levosimendan. Read more here.
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term...
Tenax Therapeutics announces reverse stock split (NASDAQ:TENX)
Tenax Therapeutics (TENX) announces a 1-for-80 reverse stock split, with trading on a split-adjusted basis to commence on January 3, 2024.
Tenax Therapeutics Announces Reverse Stock Split
CHAPEL HILL, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...